drugset / Trial / NCT00694356
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of dalotuzumab (MK-0646) in participants with relapsed or refractory locally advanced or metastatic solid tumors using once weekly and once every other week dose infusion regimens. The primary study hypothesis is that administration of dalotuzumab as a once weekly and an every other week infusion will be generally safe and well tolerated
Timeline
- Start
- 2008-08-04
- Primary completion
- 2009-03-18
- Completion
- 2009-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dalotuzumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | dalotuzumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | dalotuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |